A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2

This study is testing a new experimental drug, SBT6050, to see how it works alone or with other immune-boosting medicines. Researchers want to see if this treatment helps the immune system better identify and attack cancer cells that produce a protein called HER2.

This study is for people with advanced solid tumors that have high levels of the HER2 protein and have not responded well to standard treatments. Participants need to be generally active and able to provide a small tissue sample of their tumor for testing.

You will receive either the study drug alone or in combination with an immune-boosting medication through an IV. Throughout the study, you will have regular check-ups, scans, and blood tests to see how your body and your tumor respond to the treatment.

The study currently has locations in Boston, Durham, and Pittsburgh. The exact status of the trial is currently listed as unknown, so it is best to contact a study center directly for the most current information.